BACKGROUND: Results in breast cancer research are reported using study endpoints. Most are composite endpoints (such as locoregional recurrence), consisting of several components (for example local recurrence) that are in turn composed of specific events (such as skin recurrence). Inconsistent endpoint selection and definition might lead to unjustified conclusions when comparing study outcomes. This study aimed to determine which locoregional endpoints are used in breast cancer studies, and how these endpoints and their components are defined. METHODS: PubMed was searched for breast cancer studies published in nine leading journals in 2011. Articles using endpoints with a local or regional component were included and definitions were compared. RESULTS: Twenty-three different endpoints with a local or regional component were extracted from 44 articles. Most frequently used were disease-free survival (25 articles), recurrence-free survival (7), local control (4), locoregional recurrence-free survival (3) and event-free survival (3). Different endpoints were used for similar outcomes. Of 23 endpoints, five were not defined and 18 were defined only partially. Of these, 16 contained a local and 13 a regional component. Included events were not specified in 33 of 57 (local) and 27 of 50 (regional) cases. Definitions of local components inconsistently included carcinoma in situ and skin and chest wall recurrences. Regional components inconsistently included specific nodal sites and skin and chest wall recurrences. CONCLUSION: Breast cancer studies use many different endpoints with a locoregional component. Definitions of endpoints and events are either not provided or vary between trials. To improve transparency, facilitate trial comparison and avoid unjustified conclusions, authors should report detailed definitions of all endpoints.
BACKGROUND: Results in breast cancer research are reported using study endpoints. Most are composite endpoints (such as locoregional recurrence), consisting of several components (for example local recurrence) that are in turn composed of specific events (such as skin recurrence). Inconsistent endpoint selection and definition might lead to unjustified conclusions when comparing study outcomes. This study aimed to determine which locoregional endpoints are used in breast cancer studies, and how these endpoints and their components are defined. METHODS: PubMed was searched for breast cancer studies published in nine leading journals in 2011. Articles using endpoints with a local or regional component were included and definitions were compared. RESULTS: Twenty-three different endpoints with a local or regional component were extracted from 44 articles. Most frequently used were disease-free survival (25 articles), recurrence-free survival (7), local control (4), locoregional recurrence-free survival (3) and event-free survival (3). Different endpoints were used for similar outcomes. Of 23 endpoints, five were not defined and 18 were defined only partially. Of these, 16 contained a local and 13 a regional component. Included events were not specified in 33 of 57 (local) and 27 of 50 (regional) cases. Definitions of local components inconsistently included carcinoma in situ and skin and chest wall recurrences. Regional components inconsistently included specific nodal sites and skin and chest wall recurrences. CONCLUSION:Breast cancer studies use many different endpoints with a locoregional component. Definitions of endpoints and events are either not provided or vary between trials. To improve transparency, facilitate trial comparison and avoid unjustified conclusions, authors should report detailed definitions of all endpoints.
Authors: Anne Gulbech Ording; Deirdre Cronin-Fenton; Vera Ehrenstein; Timothy L Lash; John Acquavella; Mikael Rørth; Henrik Toft Sørensen Journal: Clin Epidemiol Date: 2016-06-11 Impact factor: 4.790
Authors: L M van Roozendaal; M L G Vane; T van Dalen; J A van der Hage; L J A Strobbe; L J Boersma; S C Linn; M B I Lobbes; P M P Poortmans; V C G Tjan-Heijnen; K K B T Van de Vijver; J de Vries; A H Westenberg; A G H Kessels; J H W de Wilt; M L Smidt Journal: BMC Cancer Date: 2017-07-01 Impact factor: 4.430
Authors: L M van Roozendaal; J H W de Wilt; T van Dalen; J A van der Hage; L J A Strobbe; L J Boersma; S C Linn; M B I Lobbes; P M P Poortmans; V C G Tjan-Heijnen; K K B T Van de Vijver; J de Vries; A H Westenberg; A G H Kessels; M L Smidt Journal: BMC Cancer Date: 2015-09-03 Impact factor: 4.430
Authors: Tom Maishman; Ramsey I Cutress; Aurea Hernandez; Sue Gerty; Ellen R Copson; Lorraine Durcan; Diana M Eccles Journal: Ann Surg Date: 2017-07 Impact factor: 12.969